Anne Schuchat*

, Tami Hilger*, Elizabeth Zell*, Monica M. Farley†, Arthur Reingold‡, Lee Harrison§, Lewis Lefkowitz¶, Richard Danila**, Karen Stefonek††, Nancy Barrett‡‡, Dale Morse§§, Robert Pinner*, and for the Active Bacterial Core Surveillance Team of the Emerging Infections Program Network
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Georgia Emerging Infection Program (Georgia Department of Human Resources, Division of Public Health, Emory University School of Medicine, and the Atlanta Veterans Administration Medical Center) Atlanta, Georgia, USA; ‡California Department of Health Services and UC Berkeley School of Public Health, Berkeley, California, USA; §Maryland Department of Health and Mental Hygiene and Johns Hopkins University School of Public Health, Baltimore, Maryland, USA; ¶Tennessee Department of Health and Vanderbilt University Medical Center, Nashville, Tennessee, USA; **Minnesota Department of Health, St. Paul, Minnesota, USA; ††Oregon Department of Human Resources, Portland, Oregon, USA; ‡‡Connecticut Department of Public Health, Hartford, Connecticut, USA; §§New York State Department of Health, Albany, New York, USA
Main Article
Table 4
Future priorities for Active Bacterial Core surveillance (ABCs) project
| 1. |
Define invasive group A Streptococcus clusters. |
| 2. |
Determine effectiveness of screening vs. risk-based prevention strategies for perinatal group B streptococcal disease. |
| 3. |
Determine feasibility of eliminating invasive disease caused by Haemophilus influenzae type b. |
| 4. |
Quantify culture-negative, polymerase chain reaction-positive meningitis. |
| 5. |
Measure direct and indirect effects of introducing a seven-valent pneumococcal conjugate vaccine. |
Main Article
Top of Page